Ben-Aharon I - Search Results

1

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.

Jacobi O, Ross JS, Goshen-Lago T, Haddad R, Moore A, Sulkes A, Brenner B, Ben-Aharon I. Jacobi O, et al. Oncol Res Treat. 2021;44(1-2):20-27. doi: 10.1159/000511919. Epub 2020 Dec 4. Oncol Res Treat. 2021. PMID: 33279901 Free article.

2

The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience.

Ben Aharon I, Purim O, Kundel Y, Brenner R, Gordon N, Sulkes A, Brenner B. Ben Aharon I, et al. Anticancer Drugs. 2012 Mar;23(3):313-20. doi: 10.1097/CAD.0b013e32834fd780. Anticancer Drugs. 2012. PMID: 22241172 Clinical Trial.

3

Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity.

Ben-Aharon I, Meizner I, Granot T, Uri S, Hasky N, Rizel S, Yerushalmi R, Sulkes A, Stemmer SM. Ben-Aharon I, et al. Oncologist. 2012;17(11):1386-93. doi: 10.1634/theoncologist.2012-0172. Epub 2012 Sep 6. Oncologist. 2012. PMID: 22956534 Free PMC article.

4

[What is the "seed of evil" mediating the pathway for the formation of metastases?].

Ben-Aharon I, Sulkes A. Ben-Aharon I, et al. Harefuah. 2013 Jan;152(1):26-7, 59. Harefuah. 2013. PMID: 23461023 Hebrew.

5

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.

Ben-Aharon I, Vidal L, Rizel S, Yerushalmi R, Shpilberg O, Sulkes A, Stemmer SM. Ben-Aharon I, et al. PLoS One. 2013 Aug 26;8(8):e70044. doi: 10.1371/journal.pone.0070044. eCollection 2013. PLoS One. 2013. PMID: 23990894 Free PMC article. Review.

6

Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.

Margel D, Benjaminov O, Ozalvo R, Shavit Grievink L, Kedar I, Yerushalmi R, Ben-Aharon I, Neiman V, Yossepowitch O, Kedar D, Levy Z, Shohat M, Brenner B, Baniel J, Rosenbaum E. Margel D, et al. BMC Cancer. 2014 Jul 21;14:528. doi: 10.1186/1471-2407-14-528. BMC Cancer. 2014. PMID: 25047061 Free PMC article. Clinical Trial.

7

Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.

Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Ben-Aharon I, et al. Acta Oncol. 2014 Sep;53(9):1230-7. doi: 10.3109/0284186X.2014.934397. Epub 2014 Aug 27. Acta Oncol. 2014. PMID: 25162954 Review.

8

Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.

Yerushalmi R, Goldvaser H, Sulkes A, Ben-Aharon I, Hendler D, Neiman V, Ciuraru NB, Bonilla L, Amit L, Zer A, Granot T, Rizel S, Stemmer SM. Yerushalmi R, et al. PLoS One. 2014 Oct 15;9(10):e107273. doi: 10.1371/journal.pone.0107273. eCollection 2014. PLoS One. 2014. PMID: 25330205 Free PMC article.

9

The impact of oxaliplatin on the gonads: from bedside to the bench.

Levi M, Shalgi R, Brenner B, Perl G, Purim O, Amit L, Stemmer SM, Ben-Aharon I. Levi M, et al. Mol Hum Reprod. 2015 Dec;21(12):885-93. doi: 10.1093/molehr/gav055. Epub 2015 Oct 6. Mol Hum Reprod. 2015. PMID: 26443807

10

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.

Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R. Lewin R, et al. Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25. Breast Cancer Res Treat. 2016. PMID: 27225387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page